Erythropoiesis after withdrawal of XXXX in post-transplant erythrocytosis.

@entity1 @entity4688 @entity8 @entity1289 @entity2178 @entity69 @entity1307
@entity4688 effectively decreases hematocrits in @entity1 with @entity8 ( @entity8 ). We studied the effect of @entity4688 withdrawal on erythropoiesis in 18 @entity1 with @entity8 who had been treated for 13 +/- 8 months. Hematocrit, reticulocyte count, plasma @entity1307 , and plasma insulin-like growth factor I were measured biweekly for six weeks. Red cell mass, plasma volume, @entity69 saturation, and plasma @entity2178 were measured at withdrawal and six weeks later. Hematocrit increased by at least 0.04 in 13 @entity1 ('responders') but changed by -0.08 to 0.01 in five @entity1 ('nonresponders'). In the responder subgroup, hematocrit increased from 0.43 +/- 0.05 to 0.51 +/- 0.05 (P < 0.001), red cell mass increased from 25.4 +/- 5.9 to 28.9 +/- 5.9 ml/kg body weight (P < 0.001), and @entity69 saturation decreased from 41 +/- 16 to 27 +/- 9 percent (P < 0.01). Reticulocyte count increased two weeks after withdrawal of @entity4688 . Plasma volume did not change significantly. No measurement changed in the nonresponder subgroup. Plasma levels of @entity1307 , total erythroid stimulating activity, insulin-like growth factor I, and @entity2178 did not change significantly in either subgroup. Enalaprilat did not inhibit erythropoiesis in cell culture. Thus, erythropoiesis increased in 13 of 18 @entity1 after stopping @entity4688 and was independent of changes in circulating concentrations of several erythropoietic factors, including @entity1307 . The pathogenesis of @entity8 and mechanism underlying the beneficial effect of @entity1289 inhibition remain undetermined.
